Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles for Hospitalized Patients With Moderate-to-Severe ARDS: A Phase III Clinical Trial

Trial Profile

Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles for Hospitalized Patients With Moderate-to-Severe ARDS: A Phase III Clinical Trial

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DB-001 (Primary)
  • Indications Adult respiratory distress syndrome; COVID 2019 infections; COVID-19 respiratory infection
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms EXTINGUISH ARDS; Extinguish Covid-19
  • Sponsors Direct Biologics

Most Recent Events

  • 19 Dec 2023 Planned End Date changed from 3 Aug 2024 to 31 Aug 2025.
  • 19 Dec 2023 Planned primary completion date changed from 3 Mar 2024 to 31 Mar 2025.
  • 19 May 2023 Planned number of patients changed from 320 to 970.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top